Cookies on this website
We use cookies to ensure that we give you the best experience on our website. If you click 'Continue' we will assume that you are happy to receive all cookies and you will not see this message again. Click 'Find out more' for information on how to change your cookie settings.

The research, funded by Parkinson's UK, reveals that an experimental drug, tasquinimod, originally developed for prostate cancer, may have the potential to treat Parkinson's disease.

Image taken by the team of Parkinson’s stem cell-derived neurons growing

The Oxford Parkinson's Disease Centre team, in a study led by Professor Richard Wade-Martins and Professor Caleb Webber, have found compelling evidence that an experimental cancer drug may have the potential to treat Parkinson's disease.

Their research, funded by Parkinson's UK, suggests that tasquinimod, a drug not yet on the market, works by interacting with a key protein inside brain cells called HDAC4. This interaction controls the activity of genes that may be critical in the development of Parkinson's. 

The team are using pioneering stem cell techniques to grow brain cells from skin cell samples, donated by both people with and without the condition.

 

More information is available on the Parkinson's UK website and the Parkinson's UK Research Blog

More detail is also available on The University of Oxford website.

Read the full Cell Stem Cell paper here.

Similar stories

New laboratory facilities for OPDC Researchers

Researchers from the OPDC and the Wade-Martins Group recently moved to brand new laboratory facilities at the Kavli Institute for NanoScience Discovery.

The brain’s one-sided teaching signals

A new study by the Lak group reveals a novel facet of dopamine signalling during visual decision making.

Fellowship awarded to Huriye Atilgan to enhance our understanding of value-based decision-making

Congratulations are in order for Postdoctoral Research Scientist Dr Huriye Atilgan who has been awarded a prestigious Sir Henry Wellcome Postdoctoral Fellowship funded by the Wellcome Trust.

The future of stroke treatment

A team of international collaborators including DPAG's Dr Mootaz Salman has been researching a promising new therapeutic for the treatment of strokes and other brain injuries.

New review reveals proof of concept for an anti-obesity immunotherapy

The Domingos lab has published a new opinion piece in Science investigating the implications of a Memorial Sloan Kettering Cancer Center study that lays the foundations for a potential new anti-obesity treatment in the form of targeting adipose tissue-resident macrophages.